Laguna Health

Language models are the whole product. The platform listens to care management conversations, extracts the life circumstances and obstacles that do not appear in a record, generates the documentation, and scores whether the care manager pursued the clues a member offered.

The company is specific about the technology rather than gesturing at it, stating that it uses large language models and that it attends to the bidirectional structure of a conversation rather than treating it as a transcript to summarise. There is no content library, no rules engine and no meaningful software product underneath: strip out the models and what remains is a dashboard with nothing to display.

Assistive on the member side and more consequential on the staff side. Care managers receive preparation, in conversation prompts and drafted documentation, and they decide what to say and what to record. The same question raised against Popai Health applies here: documentation generated from a conversation and written into the member record needs a review step, and none is described. The distinct issue here is the supervisory product.

Laguna Insight analyses 100 percent of member interactions and produces barrier detection scores assessing whether a care manager recognised and explored clues to obstacles, explicitly so that team leaders no longer listen to recordings themselves. That is a model evaluating an employee's professional judgement at scale, which is a different kind of autonomy from advising a clinician, and no published material describes whether a care manager can see, question or contest a score.

Two retrieval passes located no architecture description, no validation methodology, no accuracy figures and no publication. What is published instead is a claim that should not be made: a company representative states that the solution is accurate and hallucination free. No system built on large language models can be guaranteed free of fabrication, no method exists to demonstrate it, and the claim is unfalsifiable as stated.

It is graded here rather than treated as marketing because the whole product writes clinical documentation into a member record, which is precisely the setting where a fabricated detail does damage, and because a buyer who believes the guarantee will not build the review step that would catch one. A published error rate on generated documentation, however unflattering, would be worth more than the assurance.

There is a real evidence base underneath this product and it is not evidence for this product, which is a distinction the company's own phrasing blurs. Its material states that the solution is built on a proven contextual care model and separately that its suite is proven in published randomised clinical trials driving 50 percent cost savings and tenfold productivity gains, with no citation given and none located in two passes.

Contextual care as a clinical concept does have a published academic basis in work on contextual error, so the model being proven is credible. That a software product applying the concept produces those specific figures is a different claim requiring different evidence. This is the same split recorded against Creyos, where 400 independent studies validate a task battery and a much thinner body of work supports the commercial screener. Held at C rather than lower because the underlying concept is genuinely evidenced; the citation for the product claim is owed.

Two passes located no retention position, no minimisation statement and no policy on secondary use. The exposure is the same shape as Popai Health's and worth restating because the two records now bracket this segment: the input is recorded conversation with members about their illness, their household, their money worries and their emotional state, which is the most sensitive material a care organisation holds and the least likely to be captured anywhere else.

Nothing published describes what members are told about analysis by a third party model, how long audio or transcripts persist, or whether conversations improve the models. A product whose stated advantage is hearing what records do not contain is by construction accumulating the information people were most careful not to write down.

Two retrieval passes located no HIPAA statement, no Business Associate Agreement terms and no privacy or legal page. Graded on published posture. Agreements certainly exist, since the customers are health plans and provider organisations that could not deploy otherwise.

The gap is more visible than usual because the immediate competitor in this same segment publishes both a compliance badge and an audited security attestation on its own home page, so the comparison a buyer makes will not be against an absence of published information generally but against a peer that publishes.

Two passes located no SOC 2, no HITRUST, no ISO 27001, no trust centre and no vulnerability disclosure policy. The company states that its solution is secure, which is an assertion rather than an attestation and is the distinction this axis exists to draw.

Given that the platform ingests recorded member conversations at volume on behalf of health plans, and that a direct competitor in the same segment displays an audited report, publishing here would be straightforwardly competitive rather than merely diligent.

No clearance, authorisation or submission located and none needed. Supporting a care manager's conversation, drafting documentation and surfacing obstacles is not device functionality. As with others in this segment, the regulator that matters is not the FDA: the company names Medicare star ratings and HEDIS quality measures as explicit value drivers, which places the product inside plan quality and payment rules administered by the Centers for Medicare and Medicaid Services.

A buyer assessing this against a device framework would be examining the wrong body of law, and the questions worth asking concern documentation integrity and quality measure attribution rather than clinical safety review.

Nothing published, and two exposures compound each other in a way that is specific to this product and has not been recorded before in this index. The first is familiar: speech and language model performance varies with accent, dialect, first language, age and emotional state, and the members on these calls are disproportionately in the affected groups, since the product targets post discharge, complex care and social obstacle populations. The second is new.

Laguna Insight scores care managers on whether they noticed and explored the clues a member offered. If the model hears some members less reliably, it will detect fewer clues in those conversations, and a care manager assigned to those members will appear to have missed less because less was ever registered, or will be scored against cues the model itself misread.

Model bias therefore propagates into staff performance evaluation, and nothing published describes validation of the scoring, whether a care manager can see or contest a score, or whether scores inform employment decisions. Any vendor scoring employee conversational performance should be asked all three.

The platform states that it updates member information automatically and eliminates post call administrative work, which requires writing into whatever system of record the care management team uses, and it tailors documentation format to each organisation's conventions, which implies real integration work per customer. Two passes located no named record system, no care management platform partner, no telephony integration and no interoperability standard. The care management systems this product must sit beside are a fragmented market of their own, and which ones are supported is the first practical question a health plan will ask.

No published hosting architecture, named region or residency commitment located in two passes. As with the comparable record in this segment, the material question is whether raw audio is retained or only derived text, because a voice recording identifies the speaker independently of its content and carries a materially larger exposure than a transcript.

Nothing published distinguishes them, and nothing describes whether any component of the language model pipeline runs through an external provider, which for a product built on large language models is the first thing a security reviewer will ask.

No pricing, pricing mechanism or basis of charge located, and the claimed economics are unusually specific without being verifiable, since 50 percent cost savings and tenfold productivity are strong numbers attached to an uncited study. Total funding is stated at more than 21 million dollars including a 15 million dollar Series A co led by SemperVirens and HC9 Ventures, and no round after 2023 was located, which is a long interval for a company in a segment that has become crowded since. A health plan embedding this in care management operations should establish current funding position directly, on the supplier continuity ground this index applies from the Behold.ai precedent.

Focused on a phase of care rather than a disease, which is a coherent scope. The starting point is the transition out of hospital, where roughly two thirds of discharged patients go home to self care with paper instructions and little oversight, and coverage has extended into complex and ongoing care management.

Buyers span health plans, employers, post acute providers, home health providers and integrated delivery networks, and a separate application extends the product to family caregivers, which is a group almost nothing else in this index addresses directly. Setting is therefore the member's home and the telephone rather than any clinical facility. Held at B because it is United States only and because depth across the named buyer types is asserted rather than evidenced by named customers.